Market and Product Forecasts: Psoriasis – Novel products and current biologics to fuel future market growth
Owing to delayed competition from key contender Ozespa (briakinumab; Abbott), a favorable dosing regimen, and expansion into Japan in March 2011, Stelara will continue its ascendance in the seven major psoriasis markets (the US, Japan, France, Germany, Italy, Spain and the UK), reaching peak sales of $1,516m by 2016.
AIN457 (secukinumab; Novartis) could be the first-to-market interleukin (IL)-17 drug for psoriasis. Akin to IL brand Stelara’s superb performance to date, Datamonitor forecasts high uptake for AIN457, with sales of $252m by 2020, following launch in 2014. Making AIN457 a key growth driver of the systemic anti-psoriasis class over the next decade.
Ozespa’s future in psoriasis remains unclear, after its US and EU regulatory filings were withdrawn in January 2011, owing to safety issues. Datamonitor projects commercial success hinged on Abbott resubmitting US and EU regulatory applications. With estimated launch by 2013, its sales are forecast to reach $308m by 2020.
AIN457 (secukinumab; Novartis) could be the first-to-market interleukin (IL)-17 drug for psoriasis. Akin to IL brand Stelara’s superb performance to date, Datamonitor forecasts high uptake for AIN457, with sales of $252m by 2020, following launch in 2014. Making AIN457 a key growth driver of the systemic anti-psoriasis class over the next decade.
Ozespa’s future in psoriasis remains unclear, after its US and EU regulatory filings were withdrawn in January 2011, owing to safety issues. Datamonitor projects commercial success hinged on Abbott resubmitting US and EU regulatory applications. With estimated launch by 2013, its sales are forecast to reach $308m by 2020.
Request a Sample for or Inquire before buying the report @
http://www.reportsnreports.com/reports/143444-market-and-product-forecasts-psoriasis-novel-products-and-current-biologics-to-fuel-future-market-growth.html
http://www.reportsnreports.com/reports/143444-market-and-product-forecasts-psoriasis-novel-products-and-current-biologics-to-fuel-future-market-growth.html
Features and benefits :
Access Datamonitor’s patient based psoriasis market forecast of over 50 products in the seven major markets, with clear methodology and assumptions.
Assess current and future patient-numbers and enhance understanding of the impact future events may have on these.
Evaluate which novel products Datamonitor expects to launch over the coming decade, and how each of these will alter the market.
Gain insight into the psoriasis competitive landscape, and determine which brands drive growth.
Access Datamonitor’s patient based psoriasis market forecast of over 50 products in the seven major markets, with clear methodology and assumptions.
Assess current and future patient-numbers and enhance understanding of the impact future events may have on these.
Evaluate which novel products Datamonitor expects to launch over the coming decade, and how each of these will alter the market.
Gain insight into the psoriasis competitive landscape, and determine which brands drive growth.
Major points covered in Table of Contentsof this report include:
OVERVIEW
EXECUTIVE SUMMARY
MARKET DEFINITION
MARKET OVERVIEW AND CONTEXT
PRODUCT FORECASTS: BIOLOGICS
PRODUCT FORECASTS: SMALL MOLECULES (TOPICAL)
PRODUCT FORECASTS: SMALL MOLECULES (ORAL)
BIBLIOGRAPHY
OVERVIEW
EXECUTIVE SUMMARY
MARKET DEFINITION
MARKET OVERVIEW AND CONTEXT
PRODUCT FORECASTS: BIOLOGICS
PRODUCT FORECASTS: SMALL MOLECULES (TOPICAL)
PRODUCT FORECASTS: SMALL MOLECULES (ORAL)
BIBLIOGRAPHY
Explore Comprehensive list of more than 114 Tables & Figures available in the report Market and Product Forecasts: Psoriasis – Novel products and current biologics to fuel future market growth
No comments:
Post a Comment